siRNA Delivery Innovations in HEPATOPAC for Long Term Gene Silencing скачать в хорошем качестве

siRNA Delivery Innovations in HEPATOPAC for Long Term Gene Silencing

Oligonucleotides, such as siRNA, are broadly useful as research tools and constitute a growing class of therapeutic modalities for cell and gene therapies. However, optimization of their use in complex in vitro models is needed to leverage their research utility and facilitate therapeutic lead testing. Scott Heyward describes studies refining the treatment of siRNA in HEPATOPAC®. Knockdown and functional endpoints of ADME genes, as well as fatty liver disease-associated genes, were assessed to demonstrate the utility of HEPATOPAC for generating siRNA mediated isogenic pairs for both ADME and target screening applications. Download the slides or register for the other webinars in the series: https://info.bioivt.com/bioivt-webina... Questions, comments and requests: https://bioivt.com/about/contact-us More information on our research services and test systems: https://bioivt.com/ Other previously aired webinars: https://bioivt.com/educational-conten...) Upcoming webinar notifications: https://bioivt.com/resources/newslett... About the HEPATOPAC Webinar Series Offered as a research service or kit, HEPATOPAC® is a long-term hepatic micropatterned co-culture (MPCC) that has been shown to provide superior data, especially for low turnover compounds, compared to conventional in vitro models. HEPATOPAC has been widely used in metabolism and toxicity studies and is now being adopted for other ADME applications. The goal of providing more accurate preclinical data is the primary driving force behind the NAMs initiative that is a current focal point of regulatory agencies and industry organizations. HEPATOPAC falls under the NAMs category of Microphysiological Systems (MPS). As an established MPS, HEPATOPAC has been included in the new 3Rs Collaborative (3RsC) between regulators, technology providers, end-users, and non-profits to advance the use of MPS in regulatory applications. With the NIH’s recent announcement that they will no longer issue Notices of Funding Opportunities exclusively supporting animal models combined with the potential benefits in the regulatory review process mentioned in the announcements for the FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies, the push to utilize validated NAMs is increasing in momentum. This webinar series will evaluate the use of HEPATOPAC for a variety of applications. About the Presenter Scott Heyward, Scientific Operations Strategy Director, has worked for BioIVT for 18 years primarily in a Research and Development role working with the ADME products. He has helped to implement product improvements and new applications for our hepatic products including the use of siRNA in HEPATOPAC.